Patient-Specific Dose Modelling With Monte Carlo Methods

Monte Carlo simulation provides a detailed way to estimate how radiation is deposited in an individual patient. Instead of relying solely on analytical dose algorithms, it tracks large numbers of particles through a voxelised representation of anatomy, accounting for interactions such as scattering, absorption, secondary electron transport and energy loss. The result is a patient-specific dose distribution that can reveal differences hidden by conventional calculation methods.

For Australian medical physicists, this approach is relevant to advanced radiotherapy, stereotactic treatments, proton therapy, brachytherapy and independent dose verification. It also fits the professional culture represented by the archived COMP 2014 meeting in Banff, where clinical practice, research, education and formal governance were considered together. A reliable Monte Carlo model must therefore be scientifically sound, clinically usable and properly documented.

Why Monte Carlo Modelling Matters

Treatment planning systems commonly use algorithms designed for speed, allowing a dose calculation to be completed within a practical clinical timeframe. These methods perform well in many homogeneous or near-equilibrium situations, but their limitations can become important in lung tissue, near tissue interfaces, around small fields, within high-gradient regions and where metallic implants alter particle transport.

A Monte Carlo engine approaches the problem by sampling probability distributions for particle interactions. Repeating this process millions or billions of times produces an estimate of absorbed dose and statistical uncertainty. Increasing the number of histories generally reduces noise, although computing time, memory requirements and the efficiency of variance-reduction techniques must be managed carefully.

The calculation is only as meaningful as the patient model. CT images must be converted into material compositions and densities, treatment machine data must represent the commissioned beam, and structures such as immobilisation devices, implants and couch components may need to be included. Errors in image registration, contouring or Hounsfield-unit calibration can outweigh the apparent precision of the simulation.

Building A Patient-Specific Dose Workflow

A practical workflow begins with DICOM data: CT images, structure sets, treatment plans and, where appropriate, delivered treatment information. The CT-to-density curve is converted into a material map, while the treatment plan supplies beam energy, field shape, monitor units, gantry angle, couch angle and multileaf collimator positions. For adaptive radiotherapy, the team must also decide whether the model represents the planning scan, a repeat scan or the anatomy at a particular treatment fraction.

The transport code may be based on EGSnrc, Geant4, FLUKA or another validated platform. The choice should reflect the clinical application, available expertise and support requirements rather than software popularity alone. A research-grade code can be highly capable, but a clinical service also needs traceability, version control, repeatable input generation and a clear process for investigating failed or unusual calculations.

Education and professional assessment are part of this implementation. Staff involved in dose modelling may need to connect simulation work with radiation physics fundamentals, treatment planning and professional standards; the CCPM examination information provides useful historical context for the competency framework surrounding Canadian medical physics practice.

Australian Clinical And Regulatory Considerations

A department in Sydney, Melbourne, Brisbane or Perth may face different hardware, staffing and referral patterns, yet the underlying requirements remain consistent. Australian services often operate across public hospitals, private cancer centres and regional networks, with data transferred between sites and treatment decisions made by multidisciplinary teams. A Monte Carlo result must fit into those existing workflows rather than becoming an isolated research output.

Radiation use is governed through a combination of national guidance and state or territory legislation. ARPANSA publications, local radiation safety requirements and the relevant state regulator should inform commissioning, access controls, incident reporting and record keeping. In New South Wales, Victoria and other jurisdictions, the responsible medical physicist must ensure that advanced calculations support an authorised clinical process and do not bypass established quality assurance.

Patient information also requires careful handling. Australian Privacy Principles apply to personal information, while hospital policies may impose additional controls on cloud computing, de-identification and external software. A department considering a commercial Monte Carlo service should assess where CT data are stored, whether overseas processing is involved and how access is logged. These issues are especially important when a local market offers hosted planning, research collaborations or vendor-supported simulation platforms.

Verification, Validation And Uncertainty

Validation should proceed from simple to complex cases. Water-tank measurements can test depth-dose curves, profiles, output factors and small-field behaviour. Anthropomorphic phantoms can then assess heterogeneity corrections, oblique incidence, lung-equivalent materials, bone interfaces and clinically representative treatment geometries. Comparisons should use suitable detectors because detector size, energy dependence and spatial resolution influence the apparent agreement.

Patient-specific verification should compare Monte Carlo dose with the commissioned treatment planning system, measurements where feasible and independent checks of monitor units or delivered parameters. Agreement should be assessed using dose difference, distance-to-agreement, gamma analysis and clinically relevant metrics such as target coverage or organ-at-risk dose. A passing numerical test does not automatically demonstrate clinical acceptability if the clinically important region is poorly sampled.

Statistical uncertainty should be reported alongside the dose distribution. Low-history calculations may show visible graininess, particularly in small volumes or high-gradient areas. Reporting uncertainty maps, confidence intervals or uncertainty values for key dose-volume metrics helps clinicians distinguish biological or anatomical variation from simulation noise. Systematic uncertainties from CT calibration, beam modelling and patient setup should be considered separately from random Monte Carlo uncertainty.

Practical Checks For Clinical Deployment

A staged rollout helps a department identify technical and governance problems before patient use. Start with a defined clinical indication, such as lung stereotactic body radiotherapy or an unusual brachytherapy geometry, and specify what decision the calculation will support. The business and professional context also matters; archived committee reports and outcomes demonstrate how medical physics services connect technical work with organisational accountability.

Useful preparation can be grouped into two areas:

• Model construction: verify CT number calibration, material assignment, beam-source data, treatment-device geometry and DICOM import.
• Dose calculation: define particle histories, variance reduction, scoring resolution, calculation time and acceptable statistical uncertainty.
• Clinical review: identify who approves the result, which dose metrics are reported and when a second calculation is required.
• Data governance: document patient consent pathways, access permissions, retention periods and any external processing.

The following operational checks support consistent use during busy clinical days, when staff may move between planning rooms, treatment units and multidisciplinary meetings:

• Before calculation: confirm patient identity, image set, prescription, treatment plan version and relevant structures.
• During review: inspect dose artefacts, low-statistics regions, material overrides and unexpected changes from the reference plan.
• Before release: record the model version, calculation settings, uncertainty estimate, reviewer and clinical interpretation.
• After implementation: audit representative cases, investigate deviations and update procedures when software or hardware changes.

Documentation should be detailed enough for another physicist to reproduce the result without relying on informal knowledge. This includes input files, code versions, commissioning evidence, acceptance thresholds and records of corrective action. Australian departments may also find it useful to align the workflow with existing incident-learning systems and local quality management documentation rather than creating a separate process that staff rarely consult.

Monte Carlo simulation becomes clinically valuable when it answers a defined question with known limitations. It can clarify whether a dose calculation is credible in a difficult geometry, support safer plan evaluation and improve understanding of treatment uncertainty. It should remain a controlled component of the clinical system, supported by measurement, peer review and regular revalidation.

Medical physics teams can begin by selecting one high-value use case, assembling a representative test dataset and documenting the acceptance criteria before running patient cases. Build the model transparently, review it with radiation oncologists and radiation therapists, and use the resulting evidence to decide where patient-specific dose modelling adds genuine clinical benefit.